GS010
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Optic, Atrophy, Hereditary, Leber
Conditions
Optic, Atrophy, Hereditary, Leber
Trial Timeline
Feb 23, 2016 → Jul 4, 2019
NCT ID
NCT02652767About GS010
GS010 is a phase 3 stage product being developed by GenSight Biologics for Optic, Atrophy, Hereditary, Leber. The current trial status is completed. This product is registered under clinical trial identifier NCT02652767. Target conditions include Optic, Atrophy, Hereditary, Leber.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02652767 | Phase 3 | Completed |
| NCT02652780 | Phase 3 | Completed |
Competing Products
20 competing products in Optic, Atrophy, Hereditary, Leber
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab 120 mg | Chugai Pharmaceutical | Approved | 85 |
| Satralizumab + Placebo + Baseline Treatment | Chugai Pharmaceutical | Phase 3 | 77 |
| Satralizumab + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| PDE5 Inhibitors | Eli Lilly | Pre-clinical | 23 |
| Atacicept + Placebo matched to atacicept | Merck | Phase 2 | 52 |
| Fingolimod 0.5mg/daily + Placebo | Novartis | Phase 2 | 52 |
| satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids | Roche | Phase 3 | 77 |
| Satralizumab | Roche | Phase 3 | 77 |
| UPLIZNA | Amgen | Pre-clinical | 22 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Inebilizumab | Amgen | Approved | 84 |
| Zyvox - linezolid + Matched control | Pfizer | Phase 3 | 76 |
| Dexmedetomidine HCL Injection + Placebo | Pfizer | Phase 3 | 76 |
| No intervention | Pfizer | Pre-clinical | 22 |
| Efgartigimod Alfa + Placebo | Argenx | Phase 2 | 49 |
| Diagnostic procedures | Bayer | Approved | 82 |
| Placebo + BIIB033 100mg/Kg | Biogen | Phase 2 | 49 |
| BIIB033 (anti-LINGO-1 mAb) + Placebo | Biogen | Phase 2 | 49 |
| intravenous methylprednisolone | Brain Biotech | Pre-clinical | 15 |
| OCS-05 +SoC (corticosteroid) IV administration | Oculis Holding AG | Phase 2 | 47 |